Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

STAT+: HIV resurgence is feared as global funding to combat the disease falls 18%

Published

on

The world risks a resurgence of the HIV epidemic after international financing to combat the infectious disease suffered a “profound shock” last year, according to a new report from UNAIDS, the United Nations agency.

Overall, government funding declined by more than $1.5 billion to $7.3 billion in 2025 — an 18% decline and the lowest level in nearly two decades. Prevention programs, in particular, have historically relied heavily on donor assistance in most regions, with especially high dependency in sub-Saharan Africa, where it reached 83% two years ago.

Other factors contributing to the worrisome outlook are high debt burdens in countries most affected by the disease and backsliding on human rights and gender equality, the report noted.

Continue to STAT+ to read the full story…

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them

With more than 333,000 new cases every year, prostate cancer is the most frequently diagnosed cancer in the U.S., and by far the most common among men. It is also the least deadly: Only about 4% of prostate cancers end up being lethal, and the 5-year survival rate is about 99%. 

This paradox is in no small part due to the way it is diagnosed. A routine blood test checking for levels of a biomarker called prostate-specific antigen (PSA) is followed, if this protein is elevated, by a systematic biopsy to find cancerous tissue. This two-step process is effective at detecting cancer, even in its earliest stages. It may be too effective, in fact: Up to 70% of new prostate cancer diagnoses are low grade and in no need of treatment, as the risk of the disease turning deadly is negligible. 

Read the rest…

Read More

Published

on

With more than 333,000 new cases every year, prostate cancer is the most frequently diagnosed cancer in the U.S., and by far the most common among men. It is also the least deadly: Only about 4% of prostate cancers end up being lethal, and the 5-year survival rate is about 99%. 

This paradox is in no small part due to the way it is diagnosed. A routine blood test checking for levels of a biomarker called prostate-specific antigen (PSA) is followed, if this protein is elevated, by a systematic biopsy to find cancerous tissue. This two-step process is effective at detecting cancer, even in its earliest stages. It may be too effective, in fact: Up to 70% of new prostate cancer diagnoses are low grade and in no need of treatment, as the risk of the disease turning deadly is negligible. 

Read the rest…

Read More

Continue Reading

Uncategorized

5 NextGen winners who went public this year (and which ones are hiring)

Published

on

BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.

Continue Reading

Uncategorized

4 potential biotech M&A targets, plus a pretty sure bet from J&J

Published

on

Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.

Continue Reading
Advertisement

Trending